Development and introduction of a ready-to-use pediatric pentavalent vaccine to meet and sustain the needs of developing countries - Quinvaxem®: The first 5 years

Vaccine

Volumn 30, Issue 44, 2012, Pages 6241-6248

  Schmid, D A ^a   Macura Biegun, A ^a   Rauscher, M ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Fully liquid pentavalent vaccine; Uniject injection system

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS DIPHTHERIA TOXOID CRM197 HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID CRM197; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE; PENTAVAC; QUATTVAXEM; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

BEHAVIOR CHANGE; CONVULSION; COST EFFECTIVENESS ANALYSIS; CRYING; DEVELOPING COUNTRY; DIARRHEA; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EATING HABIT; FEVER; HEALTH CARE COST; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; IRRITABILITY; MEASLES; MUSCLE HYPOTONIA; PAIN; PERTUSSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SEROCONVERSION; SIDE EFFECT; SOMNOLENCE; TETANUS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VACCINATION REACTION; VOMITING;

CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 84865718096     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.088     Document Type: Review

References (70)

1. World Health Organization Immunization against diseases of public health importance. Fact Sheet No. 288 March 2005, World Health Organization, Geneva.
2. World Health Organization. Expanding immunization coverage, Available at: [accessed April 2012]. http://www.unicef.org/immunization/index_coverage.html.
3. World Health Organisation. Expanded Programme on Immunization, Available at: [accessed April 2012]. http://www.who.int/immunization_delivery/en/.
4. GAVI Alliance website. Available at: [accessed April 2012]. http://www.gavialliance.org/.
5. World Health Organization United Nations Children's Fund. Global Immunization Vision and Strategy 2006-2015 2005, WHO, Switzerland.
6. Decade of Vaccines Collaboration. Available at: [accessed July 2012]. http://www.dovcollaboration.org/.
7. World Health Organization Wkly Epidemiol Rec 2011, 86:509-520.
8. World Health Organization. Global Immunization Data December 2010, Available at: [accessed April 2012]. http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf.
9. World Health Organization (WHO) Expanded programme on immunization. Global Advisory Group: Part I. Wkly Epidemiol Rec 1992, 67:11-15.
10. World Health Organization The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998, 73:64-68.
11. World Health Organization (WHO) The children's vaccine initiative and the global programme for vaccines and immunization. Recommendations from the special advisory group of experts. Part I. Wkly Epidemiol Rec 1996, 71:261-266.
12. Centers for Disease Control and Prevention Combination vaccines for childhood immunization. MMWR Recomm Rep 1999, 48:1-14.
13. European Medicines Agency (EMA). Scientific discussion, Quintanrix, Available at: [accessed April 2012]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000556/WC500057288.pdf.
14. Riedemann S., Reinhardt G., Jara J., Rios R., Wenzel M.S., Willems P., et al. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. Int J Infect Dis 2002, 6:215-222.
15. Gatchalian S., Reyes M., Bernal N., Lefevre I., David M.P., Han H.H., et al. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin 2005, 1:198-203.
16. World Health Organization. Global Immunization Newsletter, 26 October 2007, p. 4.
17. Kanra G., Kara A., Demiralp O., Contorni M., Hilbert A.K., Spyr C., et al. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants. Hum Vaccin 2006, 2:155-160.
18. Gentile A., Umido V., Czerniuk P., Nacul J., Seigelchifer M., Hilbert A.K., et al. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine. Int J Infect Dis 2011, 15(1):e24-e29.
19. Aspinall S., Breedt J., Venter E., Kruger L., Van der Westhuizen T., Traynor D., et al. Safety and immunogenicity of three lots of a fully liquid DTP-HepB-Hib vaccine administered to healthy infants at 6, 10, and 14 weeks of age. Poster presentation at 24th meeting European Society for Paediatric Infectious Diseases (ESPID) 2006.
20. Aspinall S., Breedt J., Venter E., Kruger S.A., Van der Westhuizen T., Traynor D., et al. Lot-to-lot consistency study of fully liquid pentavalent DTPw-HepB-Hib vaccine demonstrates clinical equivalence and suitability of the vaccine as a booster. Poster presentation at 5th World Congress of the World Society for Paediatric Infectious Diseases (WSPID) 2007.
21. Suarez E., Asturias E.J., Hilbert A.K., Herzog C., Aeberhard U., Spyr C. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador. Rev Panam Salud Publica 2010, 27:117-124.
22. Asturias E.J., Contreras I.L., Ram M., Rivera J.G., de Melgar A.J., de Oquendo V., et al. A large, prospective observational safety study in a real life situation of cohorts vaccinated with the pentavalent combination vaccine Quinvaxem® (DTP-HepB-Hib fully liquid) when administered at 2, 4, and 6 months of age. Poster presentation at meeting of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE) 2011.
23. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus Influenzae type b. J Infect Dis 1983, 147:110.
24. World Health Organization. WHO recommendation for routine immunization-summary tables, Available at: [accessed April 2012]. http://www.who.int/immunization/policy/immunization_tables/en/index.html.
25. Joelson S., Joelson I.B., Wallander M.A. Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf 1997, 6(Suppl. 3):S31-S35.
26. Bravo L., Carlos J., Gatchalian S., Borja-Tabora C., Bibera G., Willems P., et al. The new DTPw-HBV-Hib combination vaccine can be used at the WHO schedule with a monovalent dose of hepatitis B vaccine at birth. Southeast Asian J Trop Med Public Health 1998, 29:772-778.
27. Win K.M., Aye M., Htay-Htay H., Safary A., Bock H. Comparison of separate and mixed administration of DTPw-HBV and Hib vaccines: immunogenicity and reactogenicity profiles. Int J Infect Dis 1997, 29:772-778.
28. Usonis V., Bakasenas V., Willems P., Bocks H.L. Evaluation of the immunogenicity and reactogenicity of a new combined diphtheria, tetanus, whole-cell Bordetella pertussis and hepatitis B vaccine and Haemophilus influenzae type B (DTPw-HBV/Hib) vaccine in children at 3, 4, 5 and 6 months of age. Acta Med Lituan 1999, 6:187-191.
29. Ramkissoon A., Coovadia H.M., Jugnundan P., Willems P., Clemens B.R. A new combined DTP-HBV-Hib vaccine-strategy for incorporation of Hib vaccination into childhood immunisation programmes. S Afr Med J 2001, 91:864-869.
30. Faingezicht I., Avila-Aguerro M.L., Cervantes Y., Fourneau M., Clemens S.A. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica 2002, 12:247-257.
31. Santos J.I., Martin A., De Leon T., Rivera L., Gaitan M.E., Del Rio C., et al. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine 2002, 20:1887-1893.
32. Riedeman S., Reinhardt G., Jara J., Rios R., Wenzel M.S., Willems P., et al. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. Int J Infect Dis 2002, 6:215.
33. Huu T.N., Thang H.V., Toan N.T., Phuong N.T.M., Yen D.T.T., Thuy N.D., et al. Safety of a fully liquid pentavalent DTPw-HepB-Hib combination vaccine in Vietnamese infants. Prevention Med Mag 2011, 11(6):124.
34. World Health Organization. WHO Prequalified Vaccines, Available at: [accessed July 2012]. http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/.
35. Watt J.P., Wolfson L.J., O'Brien K.L., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009, 374:903-911.
36. GAVI Alliance. GAVI role in ever-growing demand for pentavalent, Available at: [accessed April 2012]. http://www.gavialliance.org/library/news/roi/2009/gavi-role-in-ever-growing-demand-for-pentavalent/.
37. Akumu A.O., English M., Scott J.A.G., Griffiths U.K. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 2007, 85(7):501-568.
38. Broughton E.I. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis. J Public Health 2007, 29(4):441-448.
39. Gessner B.D., Sedyaningsih E.R., Griffiths U.K., Sutanto A., Linehan M., Mercer D., et al. Vaccine-preventable Haemophilus influenzae type B disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediatr Infect Dis J 2008, 27(5):438-443.
40. Gupta M., Prinja S., Kumar R., Kaur M. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan 2012, doi:10.1093/heapol/czs025.
41. Hutin Y.J.F. Comparison of three alternatives for administering DTP, Haemophilus influenzae type b, and hepatitis B vaccines through the Expanded Program on Immunization (EPI) in Bolivia. EPI Newslett 2004, 16(4):4-7.
42. Wiedenmayer K., Tediosi F., Weiss S., Chattopadhyay C., Mukherjee A.K., Kundu R., et al. Improving efficiency using a fully liquid combination vaccine: evidence from a time-motion study in India. Poster presentation at the 5th World Congress of the World Society for Pediatric Infectious Diseases 2007.
43. Augustovski F., Ferrante D., Souto A., Gadano A., Ramonet M. Análisis de costoefectividad de vacunación pentavalente totalmente liquida en argentina. Poster presentation at the X Congreso Lantin CLEN & VI Reunión de Red Iberoamericana Cochrane, Barcelona, Spain 2007.
44. Gentile A., Bhutta Z., Bravo L., Samy A.G., Garcia R.D., Hoosen A., et al. Pediatric disease burden and vaccination recommendations: understanding local differences. Int J Infect Dis 2010, 14(August (8)):e649-e658.
45. World Health Organization. Expected rates of AEFIs, Available at: [accessed April 2012]. http://www.who.int/immunization_safety/aefi/managing_AEFIs/en/index2.html.
46. Wiedenmayer K.A., Weiss S., Chattopadhyay C., Mukherjee A., Kundu R., Ayé E., et al. Simplifying paediatric immunuzation with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a time-motion study in India. Vaccine 2009, 27:655-659.
47. Gosbell I.B., Gottleib T., Kesson A.M., Post J.J., Dwyer D.E. Immunisation and multi-dose vials. Vaccine 2010, 28:656-661.
48. Drain P.K., Nelson C.M., Lloyd J.S. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull World Health Organ 2003, 81(10):726-731.
49. Jodar L., Duclos P., Milstein J.B., Griffiths E., Aguado M.T., Clements C.J. Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 2001, 19:1594-1605.
50. Stetler H.C., Garbe P.L., Dwyer D.M., Facklam M.M., Orenstein W.A., West G.R., et al. Outbreaks of group A streptococcal abscesses after diphtheria-tetanus toxoid-pertussis vaccination. Pediatrics 1985, 75(2):299-303.
51. Hutchins S.S., Jansen H.A.F.M., Robertson S.E., Evans P., Kim-Farley R.J. Studies of missed opportunities for immunization in developing and industrialized countries. Bull World Health Organ 1993, 71(5):549-560.
52. Lloyd J. Technologies for vaccine delivery in the 21st Century. Available at: [accessed April 2012]. http://whqlibdoc.who.int/hq/2000/WHO_V&B_00.35.pdf.
53. PATH. The Uniject injection system: multi-country experience and evidence. Briefing Summary. 2011.
54. Quiroga R., Halkyer P., Nelson C., Kristensen D. A prefilled injection device for outreach tetanus immunization by Bolivian traditional birth attendants. Rev Panam Salud Publica 1998, 4(1):20-25.
55. Sutanto A., Suarnawa I.M., Nelson C.M., Stewart T., Soewarso T.I. Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull World Health Organ 1999, 77(2):119-126.
56. Otto B., Suarnawa I.M., Stewart T., Nelson C., Ruff T.A., Widjaya A. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 2000, 18:498-502.
57. Abdel-Aleem H., Abol-Oyoun E.M., Moustafa S.A., Kamel H.S., Abdel-Wahab H.A. Carboprost trometamol in the management of the third stage of labor. Int J Gynaecol Obstet 1993, 42:247-250.
58. Nelson C., Widjay A., Wittet S. Using Uniject to increase the safety and effectiveness of hepatitis B immunization 2002, PATH, Seattle.
59. Nelson C., Wibisono H., Purwanto H., Mansyur I., Moniaga V., Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 2004, 82(2):99-105.
60. d'Alois L.A., Sanogo B., Millogo J., Diarra S., Plowman B. Impact of delivery technologies on increased access. TT-Uniject report, Mali. BASICS-II 2004.
61. Bahamondes L., Marchi N.M., de Lourdes Cristofoletti M., Nakagava H.M., Pellini E., Araujo F., et al. Uniject as a delivery system for the once-a-month injectable contraceptive Cyclofem in Brazil. Contraception 1996, 53(2):115-119.
62. PATH International Task Force on hepatitis B, International Vaccine Institute. Achieving universal childhood immunization with hepatitis b vaccine: policy and cost-effectiveness issues 1996, PATH, Seattle.
63. Tsu V.D., Sutanto A., Vaidya K., Coffey P., Widjaya A. Oxytocin in prefilled Uniject injection devices for managing third-stage labor in Indonesia. Int J Gynaecol Obstet 2003, 83(1):103-111.
64. Joshi N., Kumar A., Raghu M.B., Bhave S., Arulprakash R., Bhusari P., et al. Immunogenicity and safety of hepatitis B vaccine (Shanvac-B) using a novel pre-filled single use injection device Uniject in Indian subjects. Indian J Med Sci 2004, 58(11):472-477.
65. Wang L., Li J., Chen H., Li F., Armstrong G.L., Nelson C., et al. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull World Health Organ 2007, 85(9):688-694.
66. Prevention of Postpartum Hemorrhage and Initiative Pilot use of oxytocin in a Uniject device for AMTSL in Mali: evaluation of the safety and feasibility of a new delivery technology 2008, PATH, RTI International, and Engender Health, Washington, DC.
67. PATH Waste management analysis of depo-subQ in Uniject compared to DMPA intramuscular injections 2010, PATH, Seattle.
68. PATH Time and motion study with potential human papillomavirus vaccine product presentations 2009, PATH, Seattle.
69. PATH and Viet Nam Ministry of Health Reducing postpartum hemorrhage in Thanh Hoa, Viet Nam: assessing the role of active management of third stage of labor and of oxytocin in ampoules and Uniject devices 2005, PATH, Seattle.
70. Nelson C., Widya A., Wittet S. Using Uniject™ to increase the safety and effectiveness of hepatitis B immunization. PATH Occasional Paper No. 6 2002.